About Aviceda Therapeutics
Aviceda Therapeutics is a company based in Cambridge (United States) founded in 2018 by Christopher Scott, Michael Tolentino, Derek Kunimoto, and Mohamed Genead. Aviceda Therapeutics has raised $254.66 million across 5 funding rounds from investors including Marshall Wace, abrdn and Orbimed. Aviceda Therapeutics offers products and services including Selective Ligands and Pipeline Programs. Aviceda Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
- Headquarter Cambridge, United States
- Founders Christopher Scott, Michael Tolentino, Derek Kunimoto, Mohamed Genead
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$254.66 M (USD)
in 5 rounds
-
Latest Funding Round
$207.5 M (USD), Series C
Dec 17, 2024
-
Investors
Marshall Wace
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aviceda Therapeutics
Aviceda Therapeutics offers a comprehensive portfolio of products and services, including Selective Ligands and Pipeline Programs.
Compounds designed for precise immune modulation in inflammation and diseases.
Development of therapies targeting immune cells for various immunologic conditions.
People of Aviceda Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Aviceda Therapeutics
Aviceda Therapeutics has successfully raised a total of $254.66M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $207.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aviceda Therapeutics
Aviceda Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, abrdn and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Jeito Capital is focused on financing medical innovation globally.
|
Locked | Locked | Locked |
Investor details for Aviceda Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aviceda Therapeutics
Investment portfolio details for Aviceda Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aviceda Therapeutics
Detailed financials for Aviceda Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aviceda Therapeutics Comparisons
Peer comparison for Aviceda Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aviceda Therapeutics
Aviceda Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of Aviceda Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aviceda Therapeutics
Complete news archive for Aviceda Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aviceda Therapeutics
Aviceda Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Aviceda Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Mohamed Genead is the current CEO of Aviceda Therapeutics. They have also founded this company.
Aviceda Therapeutics is a funded company, having raised a total of $254.66M across 5 funding rounds to date.
Aviceda Therapeutics was founded in 2018 and is based in Cambridge, United States. Biotherapeutics targeting glycol-immune diseases are developed, with a pipeline focused on eye diseases, fibrosis, neurology, and oncology. Specific candidates include AVD-104 and AVD-302 for dry eye and diabetic retinopathy, AVD-401 for retinoblastoma, AVD-601 for oncology, AVD-701 for neurology, and AVD-801 for fibrosis. Operations center on advancing these therapies through clinical development.
Aviceda Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Aviceda Therapeutics offers Selective Ligands and Pipeline Programs.
Aviceda Therapeutics has 12 investors. Key investors include Marshall Wace, abrdn, Orbimed, Blue Owl, and Enavate Sciences.